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ABSTRACT The dermal route is an attractive route for vac-
cine delivery due to the easy skin accessibility and a dense
network of immune cells in the skin. The development of
microneedles is crucial to take advantage of the skin immuni-
zation and simultaneously to overcome problems related to
vaccination by conventional needles (e.g. pain, needle-stick
injuries or needle re-use). This review focuses on dissolving
microneedles that after penetration into the skin dissolve re-
leasing the encapsulated antigen. The microneedle patch fab-
rication techniques and their challenges are discussed as well
as the microneedle characterization methods and antigen sta-
bility aspects. The immunogenicity of antigens formulated in
dissolving microneedles are addressed. Finally, the early clin-
ical development is discussed.
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ABBREVIATIONS
Ad Adenovirus
AF4 Asymmetrical flow field–flow
fractionation
APCs Antigen presenting cells
B Brisbane
CD Circular dichroism
CpG ODN CpG oligodeoxynucleotides
DAMPs Damage-associated molecular pattern
DAB Droplet-born air blowing
dDCs Dermal dendritic cells
DEPA Dissolving microneedles on an
electrospun pillar array
DLS Dynamic light scattering
dMNs Dissolving microneedles
DT Diphtheria toxoid
ELISA Enzyme-linked immunosorbent assay
EV71 Enterovirus 71
FDA Food and drug administration
HA Hemagglutinin
HBV Hepatitis B virus
HIV Human immunodeficiency virus
HN Hemagglutinin and neuraminidase
HP-SEC Size exclusion chromatography
i.d. Intradermal
i.m. Intramuscular




MPLA Monophosphoryl lipid A
Na-CMC Sodium carboxymethylcellulose
NPs Nanoparticles
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SRID Single radial immunodiffusion assay
TEM Transmission electron microscopy
TIV Trivalent influenza vaccine
TT Tetanus toxoid
UV-Vis Ultraviolet–visible spectroscopy
VLP Virus like particles
VNT Virus neutralization test
VP Virus particles
INTRODUCTION
Vaccination is one of the most successful medical inter-
ventions in history, reducing mortality and morbidity for
several infectious diseases to almost zero in areas where
vaccines are being used (1,2). Most vaccines are adminis-
tered intramuscularly or subcutaneously (Fig. 1) by injec-
tion that may cause pain and discomfort and avoidance
by people with needle-phobia (4–7). Furthermore, the hy-
podermic needles used to administer the vaccine by these
routes generates hazardous waste and can lead to needle
stick-injuries and needle re-use. The latter can spread in-
fectious diseases such as Hepatitis B and AIDS particular-
ly in the developing countries (8). Furthermore, the use of
innovative vaccine delivery systems could offer several
other advantages such as antigen thermostability, fewer
booster immunizations and, as a consequence, increase
of the vaccination adherence and a reduced burden on
healthcare personnel. These latter advantages would es-
pecially be beneficial in mass vaccination campaigns, such
as in case of outbreaks, when feasible and fast immuniza-
tions schemes are necessary (4).
Since the skin is a very immune-competent organ and
easily accessible, dermal vaccine delivery is an attractive
alternative. The viable epidermis and dermis contain
many ant igen pre sen t ing ce l l s (APCs ) such as
Langerhans cells (LCs) and dermal dendritic cells (dDCs)
(Fig. 1) (9,10). These APCs capture antigens and subse-
quently migrate to the draining lymph nodes to present
the antigen to the T-cells to activate Ag-specific T-cells
and B-cells for systemic immune response. Besides LCs
and dDCs, epidermal keratinocytes are also involved in
the immune response by producing cytokines and
chemokines (e.g. TNF-α and IL-1β) to enhance matura-
tion of APCs and migration to the lymph nodes (11).
Although the skin surface is easily accessible, the skin (Fig.
1) is designed to protect the human body against entry of
foreign organisms or toxic substances (3,12). Therefore, the
top-layer of the skin, the stratum corneum (in humans 15–
20 μm thick), forms a significant physical barrier for vaccine
delivery. Consequently, the delivery of high-molecular weight
(>500 Da) compounds such as antigens require methods en-
abling their penetration into the skin (13). Several methods
such as powder and f lu id jet in ject ion, thermal
microporation, sonoporation, transfollicular delivery and
microneedles (9) have been proposed to deliver antigens into
the skin. Recently, microneedles (MNs) have gained great at-
tention for dermal vaccination. MNs are needle-like micro-
structures, up to 1 mm in length (3), typically assembled in
variable numbers on a patch. They pierce the stratum
corneum and underlying tissue to deliver the antigen into
the epidermis or dermis while they are short enough not to
reach pain receptors and thus pain sensation can be avoided
(7). Furthermore, the immunization with MNs may not re-
quire the healthcare personnel (5,6,11) and does not generate
sharp needle wastage after immunization.
The first microneedles were conceptualized for drug
delivery in 1976 (14) but only during the last 20 years
microneedles have been actively developed. MNs can be
classified in the following groups: hollow, coated, porous,
hydrogel-forming, dissolving microneedles (dMNs) and
MNs for pretreatment (15–18). dMNs consist of fast-
dissolving materials (e.g. polymers or sugars) as a matrix
material and the drug/antigen is mixed in the matrix.
After insertion into the skin, they dissolve releasing simul-
taneous ly the act ive pharmaceut ica l ingredient
(3,6,15,16,19).
The scope of this review is to evaluate the use of dMNs
as vaccine delivery systems to overcome the limitations of
traditional subcutaneous (s.c.), intramuscular (i.m.) or in-
tradermal (i.d.) injections. Preparation methods for dMNs,
their characterization and immunological properties will





Matrix material should possess the following characteris-
tics: biocompatible, biodegradable, low toxicity, strength/
toughness and cheap (17,20). Many materials have been
used to produce dMNs (Table I) . Head to head
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comparisons of the materials used for dMN production
have not been reported as far as we know. The selection
of the matrix material may be based on practical consid-
erations rather than rational design. Apart from safety,
factors to consider include obtaining MNs capable to
pierce the skin, compatibility with the active compound,
compatibility with the manufacturing procedure (accept-
able viscosity before drying or spraying and reasonable
solidification time) and a potential to scale-up of dMN
patches for mass production (16). The most frequently
used matrix materials are sodium hyaluronate, that is nat-
urally present in the skin, and sodium carboxymethylcel-
lulose (21–23,31–33). Both are approved as inactive ma-
terials by FDA for parenteral drug products. Other mate-
rials include poly(vinylalcohol) (PVA) (42), poly(vinylpyr-
rolidone) (PVP) (43), methylvinylether-co-maleic anhy-
dride (PMVE/MA) (Gantrez AN-139®) (44,45) and low
molecular weight sugars like maltose (46,47) and trehalose
(48). dMNs have also been prepared from biodegradable
polymers such as polylactic-co-glycolic acid (PLGA) (46),
polylactic acid (PLA) (49) and polyglycolic acid (PGA) (50).
However, due to their slow dissolution rate in skin and a
preparation method using high temperatures (34) and organ-
ic solvents, these polymers are less suitable as matrix mate-
rial. The back-plate of the dMN patch can be made by using
the same (51) or different materials (30,42) as the needles.
Furthermore, the back-plate can be reinforced or the ease of
handling can be increased by applying an adhesive tape
(38,42,52–54). Besides matrix material, other excipients
might be included ((33) (32) (30)) to improve the antigen
stability or mechanical strength of the dMNs (Table I).
Antigens that have been used include almost all vac-
cine types, ranging from peptides and proteins (21–23) to
DNA vectors encoding antigenic proteins (27,33,41) and
attenuated or inactivated viruses (26,30,31). Antigens are
generally dispersed directly in the dMN matrix
(21–23,31,32) but they can also be encapsulated in nano-
particles or in a cross-linked structure (25,28,35) to po-
tentiate or alter the immune response (25,34,35).




The most common fabrication method of dMNs is
micromolding in which dMNs are prepared using a poly-
dimethylsiloxane (PDMS) mold (Fig. 2). First, the PDMS
mold is typically produced from a silicon or metallic mas-
ter mold (17) that is obtained by using techniques such as
etching (56), lithography (57), thermal drawing (58) and
laser micromachining (59,60). PDMS is a hydrophobic
flexible material, which can very accurately reproduce
the master structure as a negative template (17). The
mold can be re-used for dMN fabrications after appropri-
ate cleaning. The first step in preparing dMNs using the
PDMS mold is the addition of the polymer/antigen




injections onto the human skin are
shown. Microneedles penetrate the
stratum corneum reaching the
viable epidermis. The hypodermic
needles puncture the skin during
insertion into the subcutaneous or
muscle tissues. Adapted from (3).
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mixture in the mold. This is typically done manually at
the research setting but the mold can also be filled by
using an atomized spray (48). After filling of the mold,
vacuum and/or centrifugation steps are performed to fill
the PDMS microcavities with the polymer/antigen mix-
ture (61). Finally, the solution in the mold is dried at
slightly elevated temperature (62,63). The drying step
c a n b e r e p l a c e d b y ph o t o p o l yme r i z a t i o n i f
photocrosslinkable material is used (60).
The micromolding can be a straightforward tech-
nique in the laboratory because it requires little addi-
tional equipment. Furthermore, the absence of harsh
conditions (e.g. high temperature or organic solvents) is
an advantage when working with sensitive antigens (64).
However, it might not be suitable for industrial scale-up
or continuous manufacturing if steps such as manual
removal of air bubbles from the microcavities after vac-
uum or centrifugation are needed or if the production
method will result in too much vaccine wastage (see
Antigen Wastage section).
Lithography
Drawing Lithography. This technique is based on extensional
(stretching) deformation of polymeric material from a 2-
dimensional to a 3-dimensional structure. Melted polymer is
Table I Overview of Matrix Materials and Antigens Used for dMN Vaccination Studies. Back-Plate Materials are Not Listed in this Table
dMN composition Antigen (Ag) Adjuvant (Adj) Ref.
Sodium hyaluronate OVA (21)
Sodium hyaluronate Adeno virus (21)
Sodium hyaluronate, dextran 70
and polyvidone
TT/DT (22)
Sodium hyaluronate TT/DT (23)
Sodium hyaluronate SE36 recombinant molecule (malaria vaccine) (23)
Sodium hyaluronate Trivalent influenza (23)
Sodium hyaluronate EV71 virus-like particles (24)
PVP OVA CpG OND (25)
Co-encapsulation in cationic liposome
PVP Whole inactivated influenza virus (26)
PVP Plasmid vector VR2012 encoding the middle
envelope proteins of HBV
CpG ODN (27)
Co-encapsulation in cationic liposome
Gantrez® AN-139 OVA Encapsulation in PLGA NPs (28)
Gantrez® AN-139 and polysorbate 80 HIV-1 CN54gp140 MPLA (29)
Sucrose and threonine IPV (30)
Maltodextrin
Sucrose, threonine and CMC Live-attenuated measles vaccine (31)
Na-CMC and trehalose Monovalent subunit influenza vaccine (32)
Trivalent subunit influenza vaccine
Na-CMC, sucrose and lactose Adenovirus expressing OVA (33)
Adenovirus expressing HIV-1 CN54 gag
PAA OVA Poly(I:C) loaded NPs (34)
PAA OVA Silk depot loading OVA (35)
poly(I:C)
Sodium chondroitin sulfate OVA (36)
Chitosan OVA (37)
Trehalose and PVA Inactivated split trivalent influenza vaccine (38)
Dextran 70 and sorbitol Trivalent subunit influenza vaccine (39)
Fish gelatin and sucrose Subunit monovalent influenza vaccines (40)
PVA and sucrose DNA plasmid expressing rabies G protein (41)
CpG ODN CpG oligodeoxynucleotides, DT diphtheria toxoid, EV71 Enterovirus 71, Gantrez® AN-139 copolymer of methylvinylether-co-maleic anhydride
(PMVE/MA),HIV human immunodeficiency virus,HBV hepatitis B virus, IPV inactivated polio vaccine,MPLAmonophosphoryl lipid A,NPs nanoparticles,Na-CMC
Sodium carboxymethylcellulose, OVA ovalbumin, PAA poly(acrylic acid), PLGA poly-D,L-lactide-co-glycolide, poly(I:C) polyinosinic-polycytidylic acid, PVA
poly(vinylalcohol), PVP poly(vinylpyrrolidone), TT tetanus toxoid
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dispensed on a fixed plate and elongated by drawing pillars in
the upper-moving plate (Fig. 2) (65,66). The polymer viscosity
is progressively increased by cooling until the glass transition
temperature of the polymer is reached. Finally, further cooling
induces a solid polymer providing the suitable dMN strength
for the skin piercing (19,66). The advantage of this fast fabri-
cation method is the minimal polymer wastage due to the
dispensed drops on the plate. However, only a limited number
of polymers have suitable glass transition temperatures for this
method (65). More importantly, this technique is not appro-
priate for thermolabile antigens because melting and transi-
tion temperatures are high during the manufacturing (e.g. for
maltose >95°C (66)).
Soft Lithography. In soft lithography dMNs are fabricated
by first pairing a polymer film with the mold with
microcavities and passing them through a heated nip.
Next, the filled mold is placed on a flexible, water-
soluble substrate and passed through the heated nip.
After separation of the mold, a dMN patch on the sub-
strate remains (Fig. 2). Instead of heated nip, photocuring
can be also used (67). Similarly to drawing lithography,
this manufacturing method claims excellent scalability,
low cost and short preparation time. However, the high
temperature used for the fabrication can be still critical
while using a thermolabile antigen mixed with the
matrix.
Droplet-Born Air Blowing and dMN on an Electrospun Pillar Array
In droplet-born air blowing (DAB), a droplet of polymer
solution without drug and another droplet of drug solu-
tion are dispensed together on two plates. The upper
plate is moved downwards so that the droplets are
Fig. 2 dMN Manufacturing Methods. See main text for details. Adapted from (66–69). DAB = droplet-born air blowing; DEPA = dMN on an
electrospun pillar array.
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touching and thereafter plates are withdrawn to a distance
corresponding to the two dMN lengths of the lower and
upper plate (Fig. 2). The polymer solutions are dried with
air flow producing a dMN patch on each plate (Fig. 2)
(68). The advantages include low temperature (4–25°C)
and fast (≤ 10 min) fabrication and minimal drug and
polymer wastage.
A variant of DAB is dMN on an electrospun pillar array
(DEPA). The flat plate is replaced here by a pillar array cov-
ered by a fibrous sheet. Then, polymer formulation droplets
are dispensed on the pillar array and placed in contact with a
PDMS slab to pull and elongate the droplets obtaining
microneedles (Fig. 2). Finally, elongated droplets are dried
by air flow.
General Challenges of dMN Preparation
Antigen Wastage
Dermal vaccination is attractive especially for the antigen
dose sparing to evoke an immune response. However, the
optimization of the manufacturing methods is crucial to
reduce antigen wastage. During micromolding part of the
antigen is lost in the PDMS mold due to low volume filling
of the microcavities relative to the system volume needed
(70). It is often mentioned that excess of solution from the
mold can be collected in order to recycle (35,51,63).
However, the saved antigen amount is often not reported
in the literature and more importantly the quality of the
recovered antigen may be difficult to guarantee hampering
reuse of the vaccine formulation.
One possibility to reduce the antigen loss during the
micromolding is to use polymer/antigen solution only
for the dMNs and to produce a backplate only from the
matrix material or even from other material. The back-
plate material should possess higher viscosity than that of
the needles to reduce the diffusion of the antigen from the
dMNs during preparation and drying (51). In stability
studies presence of antigen in the needles and its absence
in the backplate should be monitored to demonstrate lack
of diffusion of antigen to the backplate during storage
(62). However, in literature this aspect is generally not
addressed. In fabrication methods like drawing lithogra-
phy, DAB and DEPA, the antigen is dispensed in drops,
thus the antigen wastage can be potentially reduced dras-
tically. However, it is not reported if antigen can be lost in
the dispensing instrument.
Antigen and Adjuvant Loading
Besides reproducible loading (61) and dose homogeneity,
dMNs should contain a sufficient high antigen and adjuvant
dose, which can be challenging due to very low volumes of
dMN tips. This can be particularly challenging in the case of
antigens encapsulated in nanoparticles, an approach to im-
prove immunogenicity of dermally delivered subunit antigens
(28). Another aspect to consider is the delivery efficiency, i.e.
the relation between the antigen amount incorporated into
the dMNs and the antigen dose actually delivered into the
skin. Unfortunately, these aspects are often not described in
detail in the literature, although systems have been and are in
development to maximize delivery (see next section). This
makes comparison of different concepts difficult if not impos-
sible. An additional issue is the physico-chemical properties of
the adjuvant, that determines whether the adjuvant can be
mixed properly with the matrix material.
Fabrication Aimed to Improve Delivery Efficiency
In order to facilitate the delivery of the entire intended
antigen dose into the skin, some modified fabrications
have been developed. These include micromolding of ar-
rowhead dMNs mounted on mechanically strong shafts
(37,63) or dMNs presenting an elongated base increasing
the needle length (51). Drawing lithography has been
modified by dispensing melted polymer on a fixed plate
presenting pedestals (71). DEPA presents patch pillars to
improve the delivery efficiency. After patch application
into the skin, dMNs separate from the pillars due to a
tensile breaking force of the fibrous sheet between the
pillar and the dMN (Fig. 2). This allows a proper implan-
tation of the dMNs into the skin and removal of the re-
maining back plate without the need to wait dMN disso-
lution (69).
Antigen Degradation
Other critical steps during the dMNpreparation are related to
the high temperature reached in some manufacturing
methods. The micromolding usually is done at mild temper-
atures. However, when using methods such as drawing and
soft lithography, temperatures around 100°C may be re-
quired. Such a temperature can be critical when using ther-
molabile antigens mixed to the matrix. Alternatively,
photocurable polymers like acrylate-based polymers (72) and
poly (ethylene glycol) diacrylate (PEGDA) (73–75) may be
used. However, radiation should not damage proteins or
DNA of vaccines. In all methods, a drying step is included
which can be detrimental for protein antigens even at moder-
ate temperatures (76).
Sterility
Because dMNs deliver antigen into the viable skin, they
should be sterile and have low endotoxin content (77).
Since the final product is dry, a sterile filtration step, if
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at all possible, should be done on final fluid bulk, im-
plying that the actual patch manufacturing should be
performed under aseptic conditions (77). Alternatively,
sterilization of patches by gamma irradiation may be
considered, although this can damage the antigen (77)
and may be difficult to validate. Based on FDA guide-
lines for medical devices in direct contact with lymphat-




A number of unique parameters must be determined to
assess dMN quality (Table II). Since there are no licensed
products on the market, no MN monographs exist in
pharmacopoeias (79). Below, aspects that may be of im-
portance are discussed.
Appearance
Shape and sharpness of MNs are typically investigated by
microscopic techniques such as light and scanning electron
microscopy (80–84). During product development,
microscopy can be used also to analyze the distribution of
fluorescent-labelled antigen in the MNs (61).
Water Content
dMNs are dry formulations and it is important to mea-
sure their water content by using methods such as Karl
Fisher titration (a coulorimetric or volumetric titration to
determine trace amounts of water in the sample), ther-
mogravimetric analysis or moisture balance (85). The
water content can influence mechanical properties, pro-
tein stability and dissolution kinetics (81). The generally
recommended water content for freeze-dried vaccines is
less than 3% (w/w) (79), that could be also taken as
guideline for dMNs.
Antigen Stability
Stability of the antigen should be assessed both after the
manufacturing of dMNs (86) as well as after the storage
(22,24,31,38,39). The type of stability indicating assays de-
pends on the antigen as well as the type of immunity that
should be induced (e.g. for antibody responses the tertiary
structure of protein is important). Protein conformation
can be assessed by spectroscopic techniques such as
Table II dMN Characterization









Antigenicity: ELISA, SRID, virus titration
Physico-chemical characterization: intrinsic fluorescence, CD, SDS-PAGE
Aggregation: HP-SEC, NTA, MFI, AF4, TEM, DLS
Mechanical strength Displacement-force test station
Skin piercing efficiency Skin staining and histological sections
Dissolution of MNs Dissolution of MNs in vitro
Change in MN tip length after skin insertion
Antigen localization into
the skin
Microscope analysis of skin sections or confocal microscopy analysis of intact skin
Analysis of histological skin sections
Antigen quantification Quantification of antigen concentration after in vitro dissolution of dMNs by suitable
methods (e.g. UV-vis, fluorescence or ELISA)
Quantification of antigen delivered into the skin by e.g. radioactivity or infrared imaging
Stability after storage Forced (elevated humidity and temperature) and real time stability testing
AF4 asymmetrical flow field–flow fractionation, CD circular dichroism, DLS dynamic light scattering, ELISA enzyme-linked
immunosorbent assay, HP-SEC size exclusion chromatography, MFI micro-flow imaging, NTA nanoparticle tracking
analysis, SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis, SRID single radial immunodiffusion assay,
TEM transmission electron microscopy, UV-Vis ultraviolet–visible spectroscopy
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circular dichroism (80) and fluorescence spectroscopy (61).
Protein backbone integrity can be analyzed also by SDS-
PAGE (25). However, this method is not suitable to exam-
ine the protein unfolding, indicating the loss of B-cell epi-
topes. The obvious way to analyse B-cell epitopes is by
measuring antigenicity with immunoassays such as
ELISA. In case of incorporation of DNA in dMNs, agarose
gel electrophoresis and in vitro transfection can be per-
formed to measure the DNA supercoiling and efficacy re-
spectively (41).
The aggregation of protein antigens or particulate vac-
cines can be investigated by several methods such as size
exclusion chromatography (HP-SEC) (61), asymmetrical
flow field–flow fractionation (AF4) (61), micro-flow imag-
ing (MFI) (61), transmission electron microscopy (TEM)
(24), dynamic light scattering (DLS) (24) and nanoparticle
tracking analysis (NTA). For live attenuated or vector vac-
cines the viability of virus or bacterium may be sufficient
because the antigen will replicate after immunization and
so the vaccine potency can be determined by measuring
the titer of live antigen (31). Finally, immunogenicity stud-
ies are crucial to determine vaccine potency (26). A lim-
iting factor for characterization and quality control may
be the small sample sizes and matrix effects due to high
concentrations of matrix component after dissolution of
the dMNs.
So far, a few studies have systematically analyzed vac-
cine stability in dMNs. Mistilis et al. showed that the buff-
er composition and preparation conditions (e.g. drying
temperature) must be carefully selected to retain the vac-
cine stability of subunit influenza vaccine (85). ELISA
analysis of hemagglutinin activity showed that ammonium
acetate buffer (pH 7.0) and HEPES retained the antige-
nicity much better in solution and dry state than when
using phosphate-buffers. In addition, surfactants
destabilized the antigen especially in liquid formulation
prior to dMN fabrication and they may cause crystalliza-
tion of the MN matrix damaging the antigen (85). Antigen
encapsulation plays also a role in the antigen stabilization.
Similar antigen-specific CD8+ proliferative responses for
OVA-PLGA NPs in dMNs before and after 10 weeks
storage at ambient conditions were obtained (28). In con-
trast, groups immunized with 10 weeks stored monomeric
OVA in dMNs showed a decrease in T-cell response in
comparison with the group immunized with non-stored
one (28).
dMN Mechanical Strength and Skin Penetration
The mechanical properties of MNs (e.g. strength or facture
force) should be analyzed to determine whether dMNs are
strong enough and do not fracture during skin penetration
(87), unless it is intended so. Measurements of dMN
displacement-force can be performed by using a
displacement-force test station to compare different matrix
materials or geometry (80,83) or the effect of storage condi-
tions (24). Subsequent skin penetration studies are typically
analyzed on ex vivo human (61) or porcine skin (88).
However, it is also important to consider the in vitro-in vivo
correlation of the subcutaneous layers as these layers can also
affect microneedle performance. For this purpose, artificial
gel-layers can be used to resemble the in vivo situation more
closely (89). After MN application and removal from the skin,
the skin is stained with dye (e.g. trypan blue). Additionally,
stratum corneum can be stripped and the number of pene-
trating tips per patch can be determined. The penetration of
single MN through the skin layers can be examined in a de-
tailed way by analysing histological cross-sections of skin, al-
though this is a more laborious approach (37,51,80) and not
suitable for routine analysis. The depth of deposition of
fluorescently-labelled antigen in the skin can be investigated
by confocal microscopy (61) or fluorescence microscopy by
using skin cryo-sections (24).
dMN Dissolution
The analysis of the dissolution process of MNs is crucial
for reproducible antigen disposition in the skin. The
dMN dissolution time can be investigated in vitro by im-
mersing MNs in buffer (e.g. PBS) (82). This allows the
assessment of the quantity and quality of the dissolved
antigen. When focusing on dissolution in the skin, the
optimal application time of dMN in the skin can be de-
termined by analyzing MN length after the pre-
determined application periods (24,80,81). The dMN dis-
solution in ex vivo skin typically resembles the in vivo use of
MNs. However, it is important to analyze the dissolution
also in preclinical studies and in the early clinical devel-
opment because temperature and humidity conditions
may be difficult to mimic in ex vivo conditions. Careful
preclinical evaluation does not take away the need to
study microneedle dissolution in a clinical setting. The
contribution of physiological and mechanical properties
of the skin at the application site (e.g. thickness, elasticity,
etc) to the dMN dissolution rate and antigen delivery may
be substantial and should be investigated in the future.
Besides reproducible in vivo dissolution the actual dose
delivered should be determined. Actual dose delivered
can be substantially lower than the theoretical maximal
dose since the base of the microneedle has a tendency not
to dissolve completely. This is an economical risk. In that
respect arrow-shaped microneedles having a smaller base,
could have advantages above cone-shaped needles.
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Quantification of Antigen/Adjuvant Dose
In Vitro Analysis
The quantification of antigen dose in dMNs is often very
challenging and it can be done in vitro by cutting the dMNs
from the baseplate and dissolving them (81) or embedding the
dMN patch in parafilm and allow MN tips to dissolve in PBS
(90). Then, the antigen quantification can be performed for
example by fluorescence (81,90), UV-vis analysis (90) or
ELISA. The antigen amount in the dMNs can be also deter-
mined by dissolving the entire patch (MNs and back-plate)
and calculate the volume of the needles based on the needle
dimensions. In this case, a prior analysis should demonstrate
homogeneous antigen distribution in the entire patch.
However, these in vitro techniques are difficult to validate.
Furthermore, when using an adjuvant, this should also be
quantified to confirm its dose, similarly to antigen.
Ex Vivo and In Vivo Analysis
The antigen dose delivered into the skin and the reproducibil-
ity of the antigen delivery can be determined in ex vivo or in vivo
studies (63), either indirectly by measuring the remaining an-
tigen in the dissolved MNs or directly by measuring the anti-
gen in the skin. Direct quantification can be performed by
using either radioactivity (91) or infrared imaging.
IMMUNOGENICITY OF ANTIGENS
ADMINISTERED BY DMNS: PRECLINICAL
STUDIES
The first successful vaccination with dissolving microneedles was
reported in 2010 (55). Table III gives a summary of the reported
immunization studies. Depending on the antigen, a humoral
and/or cellular response is important for a therapeutic effect.
Animal Models and Application Method
Mice are the most frequently used animal model, particularly
Ba lB/c (23 ,25–27,29 ,32 ,36 ,38 ,40 ) or C57BL/6
(21,28,33–35,55) strains. Transgenic T-cell receptor mouse
models (e.g.OT-Imouse for examining CD8+T-cell response)
can be also used as immunological model (92–94). However,
animal models with skin anatomy that mimics more closely
human skin may be more relevant, for example guinea pigs
for influenza (39), beagle dogs for rabies vaccination (41) and
rhesus macaques for measles and polio vaccination (30,31).
The dMN patch can be applied either manually, particu-
larly if MN length is over 500 μm, (26–31,33,36,38,40,41) or
by using an applicator (21,22,25,37,39,55). The advantages of
the manual application are simple administration and re-
duced costs (30). However, efficient skin piercing after manual
application might be limited to longer MNs (>550 μm) while
shorter MNs (300 μm) might require an applicator (95,96).
Besides the penetration efficiency, an applicator improves
the reproducibility of the piercing, that is expected to lead to
a more reproducible delivery of the vaccine (97).
Humoral Immune Response
OVA
The model antigen ovalbumin (OVA) is most commonly used
in dMN immunization studies due to its relatively low cost and
excellent stability (98) and the strong immunogenicity in mice.
However, these beneficial characteristics mean that the results
obtained with OVA may obscure formulation problems with
more relevant vaccine antigens. Several studies with OVA-
containing dMNs have shown that IgG responses are either
equal or superior to the ones obtained by s.c., i.m. or tradi-
tional i.d. injection of the same dose (21,25,28,34,36,37,55).
Furthermore, non adjuvanted OVA dMNs (10 μg) showed a
higher response than topical application of cholera toxin-
adjuvanted OVA (100 μg) on intact skin (36). This indicates
the importance of a direct delivery of the entire antigen dose
into the skin to induce an immune response.
In another study, OVA loaded chitosan dMNs elicited
higher IgG response than i.m. injection of OVA solution after
single immunization in rats. This can be explained by a gradual
degradation of chitosan microneedles creating a depot effect in
the skin (37). The OVA containing chitosan microneedles were
mounted on a PLA support. After application, the chitosan
microneedle tips were released from the support, forming a
depot in the skin. Even two weeks after the dMN application,
chitosan andOVAwere still present in rat skin. Similarly, single
immunization with cross-linked silk/poly(acrylic acid) (PAA)
dMNs evoked higher IgG response than the i.d. injection of
OVA (35). However, in this case sustained release from the
cross-linked silk in the PAA dMNs (100% within 12 days) did
not improve the response compared to fast release from PAA
dMNs (100% within 6 days). (35). Similarly, single immuniza-
tion with Quil-A adjuvanted OVA dMNs resulted in stronger
long-lasting IgG response than Quil-A adjuvanted OVA after
i.m immunization (55). Twenty-eight days after a single immu-
nization, dMNs (dose 7.6 μg) had similar IgG response to i.m
injection (15 μg) despite the lower dose. At day 102, the IgG
response of dMNs (7.6 μg) was higher than that of i.m (15 μg),
and even more interestingly low-dose dMNs (0.4 μg) had sim-
ilar response to i.m. immunization (15 μg) (55). However, it
must be noted that dMNpatches were applied at two sites (both
ears) while i.m injection was performed only at one site.
Draining to two lymph nodes may have an effect on the
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Table III Immunization Studies with dMNs
Antigen/ Adjuvant
(dose)





Immune response analyzed dMNs result vs other groups Ref.
OVA 1 μg C57Bl/6 and Wistar
STrats
Back skin 4 times every
2 weeks
Ab response IgG levels equal or superior to






BALB/c mice Dorsal skin 2 times every
2 weeks







C57Bl/6 Dorsal ear skin 2 times every
35 days
Ab and T-cell response IgG levels comparable to the





CD8+ T-cells similar to i.d.
groups and higher than i.m.
after booster dose.
Central memory CD8+




C57Bl/6 Dorsal ear skin Single vaccination
for dMNs
Ab and T-cell response Both CD8+ and IgG response




Boost on day 28
for i.d. injection
Central memory CD8+ T-cells
higher than i.d. group
OVA 1 mg Sprague Dawley (SD)
rats





OVA 2 μg and BALB/c mice Abdomen skin 2 vaccinations after
3 weeks
Ab response IgG levels higher than i.m.
group
(25)







C57Bl/6 Dorsal ears skin Single vaccination T-cell response
and challange
In dMN group:
CD8+ T-cell response with
central and effector memory
profiles.
(28)
Manual application Growth of melanoma tumor






OVA7.6 μg / Quil-A
0.2 μg (2 patches per
mouse)
C57Bl/6 Ventral ear skin Single vaccination Ab response IgG levels (lower dose than
i.m.) higher after 102 days
than i.m. group
(55)
OVA 0.4 μg / Quil-A
0.01 μg
(1 patch per mouse)
Spring applicator IgG levels (lower dose than
i.m.) comparable after
102 days than i.m. group
Split virus influenza
vaccine 0.06 μg
(1 patch per mouse)
C57Bl/6 Ventral ear skin Single vaccination Ab response IgG levels (lower dose than








BALB/c mice Dorsal skin Single vaccination Ab and T-cell response IgG levels slightly lower
(after 14 days) and then
similar (after 28 days) than
i.m. group
(26)
Manual application HAI similar to i.m. group




BALB/c mice Ear Single vaccination Ab response Anti-HA IgG response higher
than i.m. group
(38)









Immune response analyzed dMNs result vs other groups Ref.
Inactivated split
TIV 3 μg HA
Manual application Anti-HA IgG comparable but
more durable than i.m
group





BALB/c mice Not reported 2 times after
4 weeks




lower than i.m. group





3 x 2.5 μg HA and
3 x 10.8 μg HA
Hartley guinea pigs Dorsal skin 2 times after
3 weeks





H1N1 3 μg of HA BALB/c mice Dorsal skin Single vaccination Ab response HAI, IgG and VNT higher than
i.m. group
(40)
H3N2 3 μg of HA Manual application HAI titers higher than i.m.
group
VNTand IgG titers similar to
i.m. group
B 3 μg of HA HAI, IgG and VNT higher than
i.m. group
Ad type 5 - OVA
vector (4.3 x 108 VP)
C57Bl/6 and B6 Dorsal surface of
the foot, ear or
back skin
Single vaccination T-cell response SIINFEKL- specific CD8+
T-cells indistinguishable with
i.d., s.c. and i.m. groups
(33)
Ad type 5 – HIV/gag
vector (4.3 x 108 VP)
Manual application CD8+ T-cell frequencies
comparable with i.d. group
Ad (7.7 x 109 VP) Hairless rats Back skin 3 times after
2 weeks
Ab response IgG titers equal to s.c. group (21)
Handheld
Applicator
EV71 VLP 1 μg BALB/c mice Dorsal skin 3 times after
2 weeks
Ab, T-cell response and
challenge
IgG and VNTcomparable to
i.m.(10 μg) and higher than
s.c. (10 μg) after the third
vaccination
(24)
Applicator 100% survival after challenge
Stronger T-cell response than
i.m. and s.c. (both 10 μg)
IPV type 1
(47 D-antigen units)
Rhesus Macaques Upper back skin 2 times after
8 weeks
Ab response No difference in IgG




Manual application No difference in IgG
responses with i.m. group
IPV type 3
(38 D-antigen units)
IgG lower than in the i.m.
group.
This difference is due to a
mistake in the IPV type 3
quantification: the real dose
in the patch was 3x lower
than 38 D-antigen units
Divalent toxoid
vaccine (TT 20 μg
and DT 10 μg)
Wistar STrats Back skin 5 times after
2 weeks
Ab response Both anti-TTand anti-DT
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magnitude of the response. Also, the ear is a very sensitive
location for dermal vaccination probably for the short distance
to one major draining lymph node (99).
The use of dMNs have been shown to affect the Th1/Th2
balance. Single immunization with cross-linked silk/PAA
dMNs evoked strong IgG1 and IgG2c response while i.d. in-
jection elicit only IgG1 response, and thus dMN immuniza-
tion shifted Th1/Th2 balance toward Th1 (35). These results
were supported by another study where hyaluronan-based
OVA dMNs were compared to s.c. and i.d. injections in mice
(21). In contrast, in rats no IgG2c response was detected nei-
ther after dMN, s.c., or i.d. immunization in the same study
(21). Additionally, in another study the shift in Th1/Th2 bal-
ance was not observed after dMN immunization in mice (25).
As conclusion, dMN vaccination may affect the Th1/Th2
balance but further studies are needed since the number of
publications on this subject is limited.
Influenza
Immunization with influenza vaccine loaded dMNs resulted
often in higher ((38) (40)) or comparable (26) IgG response than
i.m. administration. However, Kommareddy et al. showed that
dMNs evoked lower IgG response than i.m. immunization
after the boost, although the response induced by dMNs was
higher after the prime (32). However, in other studies
contradicting results were found. Haemagglutination inhibi-
tion titers and antibodies and neutralizing antibody titers
after the dMN immunization were similar (26) or superior
(40) to i.m. immunization. Stabilization of the antigen by ad-
dition of sucrose (40) may have allowed to obtain a higher
antibody titers than the previous work (26). Furthermore, the
difference with the above mentioned study (32) could be ex-
plained by the use of a different assay (ELISA assay) than the
one routinely used to investigate the influenza vaccine quality
(single radial immunodiffusion (SRID) assay). Interestingly, the
dry matrix of dMNs can stabilize the antigen up to one year in
comparison to liquid formulation (38). In summary, most stud-
ies show that influenza vaccination by dMNs can evoke com-
parable or even superior responses than i.m. immunization.
Other Antigens
Different types of antigen, such as vector, live attenuated and
inactivated vaccines, have been loaded in dMNs and evaluat-
ed in vivo. An example is the vaccination of rats with the model
antigen adenovirus (Ad) loaded dMNs: Ad-specific IgG titers
observed were comparable to the s.c. group, while topical
application showed no IgG response (21). In a study examin-
ing the dose-sparing effect, mice were immunized with dMNs
loaded with 1/10th the dose of Enterovirus71 (EV71) – virus-









Immune response analyzed dMNs result vs other groups Ref.
Measles Vaccine
(3100 TCID50)
Rhesus Macaques Upper back skin Single vaccination Ab response VNT titers equivalent to







BALB/c mice Abdominal skin 2 times after
3 weeks
Ab response IgG comparable to i.m. group (27)







Beagle dogs Inner ear pinna 2 times after
4 weeks
Ab response VNT titers comparable
(42 days after the prime) and
higher (56 days after the







VNT titers lower than i.m.
group
HIV-1 CN54gp140
10 μg MPLA (20 μg)
BalB/c Ear 4 times after
2 weeks
Ab response IgG titers lower than s.c. group (29)
Application by
thumb
Ad adenovirus, B Brisbane, CpG ODN CpG oligodeoxynucleotides, DT diphtheria toxoid, EV71 Enterovirus 71, HA hemagglutinin, HBV hepatitis B virus, HIV
human immunodeficiency virus, HN hemagglutinin and neuraminidase, IPV inactivated polio vaccine, MPLA monophosphoryl lipid A, NPs nanoparticles, OVA
ovalbumin, PLGA poly-D,L-lactide-co-glycolide, poly(I:C) polyinosinic-polycytidylic acid, TIV trivalent influenza vaccine, TT tetanus toxoid, VLP virus like particles,
VNT virus neutralization test, VP virus particles
2234 Leone, Mönkäre, Bouwstra and Kersten
and s.c. injected vaccine. Antibody and neutralizing titers both
revealed comparable responses to i.m. and higher responses
than s.c. after the three immunizations. Furthermore, the
dMN group, together with s.c. and i.m. groups, survived the
lethal virus challenge showing the protective effect of the
dMNs (24). Rhesus macaques were used as animal model to
examine the immune response after vaccination with
inactivated polio vaccine (IPV) (30) and live-attenuated mea-
sles vaccine (31). In both cases, neutralizing antibody titers
after dMN immunization were comparable to that after s.c.
(measles) and i.m. (IPV) immunization.
In the case of dMNs loaded with DNA containing the ra-
bies G-protein gene, comparable neutralizing antibody titers
with i.m. were detected after a booster. No evidence of the
dose sparing in dMNs was found since the antibody titers of
10-fold lower dose were clearly weaker than those of full dose
in dMNs (41). The co-encapsulation of plasmid vector against
hepatitis B virus (HBV) and CpG in cationic liposomes in
dMNs resulted in slightly higher IgG titers than free antigen
and adjuvant in dMNs (27). It should be considered that the
characteristics of liposomes changed after loading in dMNs
(increase in size and decrease in Z-potential). However, the
immune responses were generally similar between dMN and
i.m immunization, and adjuvant and liposomes did not affect
the IgG1/IgG2a balance (27).
Cellular Immune Response
De Muth et al. have reported two studies in which dMN im-
munization elicited high CD8+ T-cell responses. Mice were
immunized with dMNs made of fast-dissolving PAA contain-
ing OVA mixed with PLGA microparticles (size 1.6 μm) en-
capsulating poly(I:C) (34) or cross-linked silk structure of OVA
and poly(I:C) (35). The latter results in a binary release profile:
a burst of OVA after dMN dissolution followed by a sustained
OVA release from the cross-linked silk structure. Both studies
indicated that the CD8+ T-cells producing IFN-γ and
TNF-α, upon peptide stimulation, are increased by dermal
sustained release (>16 days) from dMNs in comparison with
i.m. injection of sustained release of poly(I:C) from PLGA
microparticles (34), or with i.d. injection of soluble OVA and
poly(I:C) (35). Furthermore, when comparing the different
dMNs, the sustained release of cross-linked silk/PAA
microneedles additionally increased the CD8+ response in
comparison with fast release of PAA microneedles (35). In
addition, a prime immunization with dMNs can produce a
similar fraction of functional CD8+ T-cells as a prime and
boost with i.d. injection (35). Despite a larger effector CD8+
T-cell response, dMN delivery also resulted in a more rapid
transition to central memory CD8+ T-cells than i.m. and i.d.
injections, suggesting the additional expansion of CD8+ T-
cells after dMN delivery did not solely result in more termi-
nally differentiated effector cells (34) (35). However, sustained
release from dMNs did not further improve the memory re-
sponse (35). A long-term memory immune response was re-
ported also after vaccination by Na-CMC dMNs loading re-
combinant adenovirus vector encoding HIV-1 gag.
Vaccination by dMNs generated CD8+memory T-cells com-
parable with the intradermal injection (100). Supporting re-
sults have been found also with other MN technologies induc-
ing a better long-term memory response than s.c. (101) or i.d.
(102) injections.
The PLGA NPs dMN concept may have potential for
therapeutic cancer vaccination: dMN immunization sup-
pressed the growth of melanoma tumor, evoked in mice by
injecting OVA-tumor cells, through antigen-specific CD8+ T
cells (28). Furthermore, OVA-PLGA NPs dMN immuniza-
tion protected against respiratory viral challenge with a re-
combinant Sendai virus expressing OVA (28). The vaccine
depot and particulate vaccines may induce a better T-cell
immune protection because the response correlates with anti-
gen persistence (103), the sustained antigen release (104) or
particulate nature of vaccine. To elucidate the immunological
mechanism, it was shown that Langerhans cells are required
for cytotoxic CD8+ responses (28) (105). Langerhans cells
apparently efficiently process the OVA loaded in the micro-
particles which leads to cross presentation by MHC class I
molecules. To support this explanation, the role of
Langerhans cells was less significant for soluble OVA com-
pared to particulate OVA (105).
In another study with dMNs loaded with EV71 virus-like
particles, vaccination by dMNs loading 10 times lower antigen
dose than i.m. and s.c. injections could promote stronger EV71-
specific T-cell response than the conventional injections (24).
Viral vectors are able to induce strong T-cell responses
after dMN immunization. dMNs with human adenovirus ex-
pressing ovalbumin were compared to i.d, i.m. and s.c. injec-
tions. The T-cell responses were similar in all groups (33).
Similarly, CD8+T-cell responses were comparable after mice
were immunized with rAdHu5 vector encoding a HIV-1 Gag
gene by dMNs or i.d. injection (33).
dMN Immunization: Factors Influencing
the Immunogenicity
Adjuvants
Several adjuvants have been used in dMNs and they are sim-
ilar to those used for other administration routes except alu-
minum based adjuvants and emulsions. Aluminium based ad-
juvants may cause local adverse effects like granuloma forma-
tion and therefore is not suitable for delivery to the skin (106).
Emulsions cannot be formulated in dry formulations like
dMN because water is a structural part of the formulation.
Molecular immune modulators, such as CpG (25,27),
poly(I:C) (34), Quil-A (55), monophosphoryl lipid A (MPLA)
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(29) and imiquimod (107) have been used in dMNs. In gener-
al, a significant increase in the immune response is observed
when an adjuvant is included in dMNs (25,27), although
sometimes the control group without the adjuvant is lacking.
Unfortunately, the rationale of selection a certain adjuvant
and its dose has not often been addressed.
Delivery systems can be formulated into dMNs (see previ-
ous section). Similarly to other administration routes, encapsu-
lation of antigen (and adjuvant) in nanoparticles or liposomes
can enhance the immune response after delivery with dMNs
(25,27,28) as described above (Humoral Immune Response
and Cellular Immune Response Sections). Adjuvants are often
needed with modern subunit vaccines but their use might be
avoided with attenuated viruses and viral vectors. Absence of
adjuvant would also facilitate batch release since adjuvant
quantification is not needed and antigen quantity is often lim-
ited to a simple plaque titration or colony count as opposed to
an immunogenicity test in experimental animals.
MNs Spacing and MN Geometry
Modelling studies have indicated that the MNs spacing may
affect the immune response by contributing to the optimal
antigen concentration released into the skin to activate APC
located between the MNs (108). However, this is not experi-
mentally confirmed and factors not accounted for in the mod-
el may contribute significantly to the immunogenicity.
The MN length may influence the population of APCs
activated so that shorter MNs could activate LCs in the epi-
dermis and longer MNs could activate dDCs in the dermis
(108). In vivo studies with 1 μg OVA showed that IgG response
after vaccination by dMNs of 300 and 800 μm in length is
higher than using dMNs of 200μm in length (21). On the other
hand, the variation of injection depth with hollowMNs did not
affect the immune response (109). However, while a controlled
antigen dose was released at different skin depth by hollow
microneedles (109), not clear is the antigen dose released into
the skin from the dMN of different lengths (21). This could
explain the difference in the immune response.
Apart from MN length, needle density may be an impor-
tant variable with respect to immunogenicity. The needles
cause minor damage and cell death, initiating a pathway act-
ing as Bnatural immune enhancer^mediated by the release of
damage-associated molecular patterns (DAMPs) (110). In fact,
the same antigen dose released by coated MNs elicited higher
response than a single i.d. injection (110).
CLINICAL DEVELOPMENT OF DISSOLVING
MICRONEEDLES
dMNs are a relatively new vaccine delivery system with no
licensed vaccines and few results from clinical studies. Two
phase 1 (safety) studies with microneedles without antigen
have been performed so far. In the first, hyaluronan
microneedles (length 300, 500 and 800 μm, 200 dMNs
on a 0.8 cm2 patch) have been applied on 17 subjects
(53). Despite a successful dMN penetration into the skin
by using an applicator, the microneedles required 6 h of
application for nearly complete dissolution in all subjects,
which may be too long for routine immunization. In the
second study, PVA microneedles (length 650 μm, 100
dMNs on a 1 cm2 patch) have been applied on 15 subjects
(111). In this case, an average of 100% piercing efficiency
of MNs into the skin without any applicator use was
reached. However, variance in the microneedle volume
dissolved, especially among subjects using self-administra-
tion, underlined the importance of using an applicator to
have a controlled force and an impact during application.
Few subjects (53) or all of them (111) showed a slight ery-
thema after dMN application that disappeared within
7 days. However, longer dMNs of 500 and 800 μm caused
purpura, indicating capillary damage, in 50% of the vol-
unteers but shorter 300 μm dMNs did not induce any
purpura (53). No swelling at the application site (111) or
systemic adverse events were observed (53). Additionally, it
was also concluded that dMN application caused hardly
(53) or no pain (111).
In another clinical phase 1 study, trivalent influenza hem-
agglutinins vaccination with sodium hyaluronate dMNs
(800 μm, 200 dMNs on a 0.8 cm2 patch, spring-type applica-
tor used) was investigated in healthy subjects (112). dMNs
loaded with 3 x 15 μg of influenza antigens on a single patch,
were compared with the same dose administered by s.c. injec-
tion. During the prime immunization a proper dMN dissolu-
tion was observed in only seven subjects out of 20 and only
these subjects were included in the final analysis. Furthermore,
the applicator settings were changed to obtained a more effi-
cient application in the second vaccination. After the prime,
the anti-HI antibody titers against influenza A HA-antigens
(H1N1 and H3N2 strains) were equivalent in the dMN and
s.c. groups, except that for the B strain that showed higher
titers in the dMN group also observed in preclinical studies
(32). More IFN-γ-producing peripheral blood mononuclear
cells were detected after s.c. than dMN immunization (112).
However, the low number of subjects in dMN group limits the
conclusions. Regarding the safety, erythema detected in the
dMN group was higher than the s.c. one and more pro-
nounced than in the previous clinical studies (53,111).
Purpura was observed in 50% of the subjects both in the
dMN and the s.c. group. However, no adverse systemic events
were observed (112).
These studies prove that the applicator and its settings have
a crucial role for MN penetration and subsequent dissolution
into the skin. Alternatively, encapsulation of the antigen only
in the microneedle tip can enable a complete antigen delivery
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even with incomplete microneedle dissolution (e.g., localizing
the antigen in the upper 70% of the MNs, a 70% dissolution
would correspond to 100% antigen delivery).
Besides above mentioned studies, at least one other study
has been performed to investigate safety and immunogenicity
of influenza vaccination with dMNs but the results are not yet
published (113).
CONCLUSIONS AND PROSPECTS
dMN vaccination can offer important advantages such as dose
sparing, pain-free immunization and avoidance of needle-
stick injuries. Furthermore, it can extend the vaccination cov-
erage in developing countries by potentially offering improved
vaccine stability, reduction of vaccine wastage and of burden
on trained personnel. However, several improvements are still
needed in some areas of dMN development before the regu-
latory acceptance and industrial scale-up are feasible.
Fabrication methods require further optimization to enable
the minimal wastage of antigen that is often claimed but rarely
reported in the literature, and not yet proven on at least pilot
scale production level. Analytical challenges include potency
testing and stability testing during fabrication and storage, and
quantification and reproducibility of antigen/adjuvant dose
delivered in the skin. Furthermore, the role of the applicator
device should not be underestimated because it can standard-
ize dMN application and vaccine delivery into the skin, al-
though with respect to logistics manual application is pre-
ferred. dMN immunization has generated comparable or
higher andmore durable antibody and cellular responses than
conventional immunizations in preclinical studies.
Additionally, sustained release of antigen from nanoparticles
or cross-linked structures in dMNs showed to induce a better
cellular immune response than fast release from dMNs or
liquid solution, although the sustained release from dMNs
did not improve further the humoral response than fast release
from dMNs. However, further studies should be performed to
support this conclusion. In the future, more systematic studies,
such as identification of optimal adjuvants and analysis of
effect of dMN geometry, may be necessary to optimize
dMN immunization. Until now, three clinical phase 1 studies
have been reported and showed that skin irritation and patch
application are hurdles that need to be solved in future appli-
cations. The ideal dMN patch (Table IV) does not exist yet
but encouraging progress has been made. More work is need-
ed to further develop dMNs into safe, efficacious, affordable
and widely used products.
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